Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Cynvenio, ATGen Initiate Pilot Study of Combo Cancer Test

Cynvenio, ATGen Initiate Pilot Study of Combo Cancer Test

Dec 28, 2015
|
staff reporter

NEW YORK (GenomeWeb) – Cynvenio Biosystems announced today that it has launched a pilot surveillance study with South Korea's ATGen Global to evaluate a new method for the early detection of cancer recurrence in triple-negative breast cancer patients. Cynvenio's ClearID test will be combined with ATGen's NK Vue blood test to detect cancer recurrence in women who have previously been treated for triple-negative breast cancer and show no radiographic signs of metastases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Extension Call

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

All Along the Axon

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

For the Accelerator

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

Science Papers Describe New Cas9 Variant, Atlas of Human Metabolism

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

What's Popular?

In Business News

  1. Fosun Long March Gets Chinese Regulatory Approval for Coronavirus MDx Kit

  2. Danaher Prices €1.7 Billion Offering of Senior Notes

  3. GigaMune Hopes to Offer TCR Screens to Pharmas While Scrambling to Keep Expression Libraries Alive

    Premium

  4. Biocept More Than Doubles Q4 Revenues; Full-Year Revenues Grow 70 Percent

  5. Biocartis, Immunexpress Ink Co-Commercialization Agreement for Sepsis Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.